Genetic substrates of psychosis in patients with Parkinson's disease: A critical review

  title={Genetic substrates of psychosis in patients with Parkinson's disease: A critical review},
  author={Abhishek Lenka and Shyam Sundar Arumugham and Rita Christopher and Pramod Kumar Pal},
  journal={Journal of the Neurological Sciences},

Psychosis in Parkinson’s Disease: A Lesson from Genetics

This work reviewed and critically analyzed recent studies exploring the genetic architecture of psychosis in PD in order to further understand the pathophysiology of PDP, the risk factors as well as the most suitable therapeutic strategies.

Emerging role of psychosis in Parkinson's disease: From clinical relevance to molecular mechanisms

In this opinion review, the identification, screening, epidemiology, mechanisms, risk factors, and therapeutic approaches of PD psychosis are summarized and analyzed based on the current clinical evidence.

Psychosis in Parkinson's disease: From the soft signs to the hard science

Clinical and Genetic Analysis of Psychosis in Parkinson's Disease.

Besides previous exposure to dopaminergic drugs, impairment of motor status, depression and anxiety, as well-established clinical risk factors for the development of PDP, GG rs2734849 ANKK1 could also be a contributing factor, which requires addressing by future longitudinal studies.

Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management

The serotonin 5-HT2A receptor inverse agonist pimavanserin was recently approved by the US FDA for the treatment of PDP and may prove to be a more targeted therapy without the downsides of atypical antipsychotics.

The Neuropsychiatry of Parkinson Disease: A Perfect Storm.

  • D. WeintraubE. Mamikonyan
  • Psychology, Medicine
    The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • 2019

The psychosis spectrum in Parkinson disease

This work discusses recent developments, including recognition of an increase in the prevalence of psychosis with disease duration, addition of new visual symptoms to the psychosis continuum, and identification of frontal executive, visual perceptual and memory dysfunction at different disease stages.

Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin.

A selective 5-HT2A inverse agonist, pimavanserin, has been developed, investigated and has gained approval in April 2016 in the US for the treatment of hallucinations and delusions in PD.

Psychiatric Comorbidities in Parkinson's Disease Seen through the Prism of Genomics and Epigenetics.

New insights in the genomic and epigenetic background of psychiatric comorbidity in Parkinson's disease are presented.



Pathophysiology and Treatment of Psychosis in Parkinson’s Disease

Case reports suggest that electroconvulsive therapy has the potential to reduce psychotic symptoms and may be considered in cases involving concurrent depression and/or medication-refractory psychosis, and case reports also suggest that specific antidepressants may improve psychosis in depressed patients.

Epidemiology of psychosis in Parkinson's disease

Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease

Dementia in PD was related to older age of symptoms onset and old age, and depression seemed to contribute to the appearance of psychosis even more than dementia, especially in patients with younger age of Symptoms onset.

Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations

The matched case-control study did not replicate the association between CCK or CCKAR polymorphisms and increased hallucination risk in white PD patients with chronic hallucinations, and there were no significant differences between PD hallucinators and non-hallucinators in age, gender, disease duration, or levodopa equivalent doses.

Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease.

Compared the frequency of polymorphisms in the dopamine D2 and D3 receptor genes between patients with drug-induced hallucinations and non-hallucinating patients, an association was found with late-onset hallucinations and the C allele of the TaqIA polymorphism.

Psychosis in Parkinson's Disease: Phenomenology, Frequency, Risk Factors, and Current Understanding of Pathophysiologic Mechanisms

Hallucinations may involve several sensory modalities and include visual illusions, passage hallucinations, and sense of presence in Parkinson's disease patients with cognitive impairment.

Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease.

Genetic variation in DRD1 and DRD3 genes may act to modify the course of AD, predisposing to the development of psychotic or aggressive symptoms.

Course, Prognosis, and Management of Psychosis in Parkinson's Disease: Are Current Treatments Really Effective?

It is essential to recognize and treat psychosis in Parkinson's disease for several reasons, and an atypical antipsychotic is presently the treatment of choice.

No association of COMT val158met polymorphism and psychotic symptoms in Lewy body dementias